Rheumatology and bone disease

Published on 03/03/2015 by admin

Filed under Internal Medicine

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 2922 times

Chapter 11 Rheumatology and bone disease

Rheumatological and musculoskeletal disorders

Many common locomotor problems are short-lived and self-limiting or settle with a course of simple analgesia and/or physical treatment; e.g. physiotherapy or osteopathy. However, they represent 20–30% of the workload of the primary care physician, where non-inflammatory problems predominate. Recognition and appropriate early treatment of many painful rheumatic conditions may help reduce the incidence of chronic pain disorders. Early recognition and subsequent treatment of inflammatory arthritis by specialist multidisciplinary teams leads to better symptom control and prevents long-term joint damage and disability. The patient should always be included when decisions about treatment are being discussed. Pamphlets and websites offer helpful advice for patients, and their use should be encouraged.

The normal joint

There are three types of joints: fibrous, fibrocartilaginous and synovial.

Juxta-articular bone

The bone which abuts a joint (epiphyseal bone) differs structurally from the shaft (metaphysis) (see Fig. 11.32). It is highly vascular and comprises a light framework of mineralized collagen enclosed in a thin coating of tougher, cortical bone. The ability of this structure to withstand pressure is low and it collapses and fractures when the normal intra-articular covering of hyaline cartilage is worn away as in osteoarthritis (OA; see p. 512). Loss of surface cartilage also leads to the abnormalities of bone growth and remodelling typical of OA (see p. 512).

Ligaments and tendons

These structures stabilize joints. Ligaments are variably elastic and this contributes to the stiffness or laxity of joints (see p. 559). Tendons are inelastic and transmit muscle power to bones. The joint capsule is formed by intermeshing tendons and ligaments. The point where a tendon or ligament joins a bone is called an enthesis and may be the site of inflammation.

Components of extracellular matrix

All connective tissues contain an extracellular matrix of macromolecules: collagens, elastins, non-collagenous glycoproteins and proteoglycans, in addition to cells, e.g. synoviocytes. There are several different types of cell surface receptors that bind extracellular matrix proteins including the integrins, CD44 and the proteoglycan family of receptors, e.g. syndecans.

Collagens. Collagens consist of three polypeptide (α) chains wound into a triple helix. These alpha chains contain repeating sequences of Gly-x-y triplets, where x and y are often prolyl and hydroxypropyl residues. Collagen fibres show genetic heterogeneity, with genes on at least 12 chromosomes. Hyaline cartilage is 90% type II (COL2A1). There are several classes of collagen genes, based on their protein structures, and abnormalities of these may lead to specific diseases (see p. 560).

Elastin, secreted as tropoelastin, is an insoluble protein polymer and is the main component of elastic fibres.

Glycoproteins. Fibronectin is the major non-collagenous glycoprotein in the extracellular matrix. Its molecule contains a number of functional domains, or cell recognition sites that bind ligands and are involved in cellular adhesion. Fibronectin plays a major role in tissue remodelling. Its production is stimulated by interferon-gamma (IFN-γ) and by transforming growth factor-beta and inhibited by tumour necrosis factor and interleukin-1.

Proteoglycans. These proteins contain glycosaminoglycan (GAG) side-chains and are of variable form and size. Many different molecules have been identified at different sites in connective tissue. Their function is to bind extracellular matrix together, retain soluble molecules in the matrix and assist with cell binding. Abnormalities of any of these structures may lead to periarticular or articular symptoms and/or predispose to the development of arthritis.

Skeletal muscle

This consists of bundles of myocytes containing actin and myosin molecules. These molecules interdigitate and form myofibrils which cause muscle contraction in a similar way to myocardial muscle (p. 671). Bundles of myofibrils (fasciculi) are covered by connective tissue, the perimysium, which merges with the epimysium (covering the muscle) and forms the tendon which attaches to the bone surface (enthesis).

Clinical approach to the patient

Taking a musculoskeletal history

The following questions are helpful in assessing the problem and making a diagnosis. A history can often lead to a diagnosis as pattern recognition is the key to diagnosis in rheumatic diseases.

Gender

Gout (see p. 530), reactive arthritis (p. 529) and ankylosing spondylitis (p. 527) are more common in men. Rheumatoid arthritis and other autoimmune rheumatic diseases are more common in women.

Age

image Is the person young, middle-aged or older?

image How old was the patient when the problem first started? Osteoarthritis (see p. 512) and polymyalgia rheumatica (p. 542) rarely affect the under-50s. Rheumatoid arthritis starts most commonly in women aged 30–50 years.

Examination of the joints

Always observe a patient, looking for disabilities, as he or she walks into the room and sits down. General and neurological examinations are often necessary. Guidelines for rapid examinations of the limbs and spine are shown in Practical Box 11.1.

image Practical Box 11.1

Rapid examinations of the limb and spine

Examining an individual joint involves three stages: looking, feeling and moving (Table 11.1). A screening examination of the locomotor system, known by the acronym GALS (Global Assessment of the Locomotor System) has been devised. X-ray or ultrasound of the joint often forms an integral part of the examination.

Table 11.1 Examination of the joint

LOOK at the appearance of the joint

Swelling – could be bony, fluid or synovial

Deformity – valgus, where the distal bone is deviated laterally (e.g. knock-knees or genu valgum)

 Varus where the distal bone is deviated medially (bow-legs or genu varum)

 Fixed flexion or hyperextension

Rash – especially psoriasis

Muscle wasting – easier to see in large muscles like the quadriceps

Scars – from surgery or trauma

Signs of inflammationSymmetry – are the right and left joints (e.g. hips, knees, any other paired joint) the same? If not which do you think is abnormal?

FEEL

Swelling – fluid swelling (effusion) usually represents increased synovial fluid in inflammatory arthritis, but can be due to blood or pus

 Synovial swelling is rubbery or boggy and usually occurs in inflammatory arthritis

 Bony swelling, such as Heberden’s nodes in the fingers is usually seen in osteoarthritis

Warmth – a warm joint may be inflamed or infected

Tenderness – may represent joint inflammation, but many people have chronic tenderness all over the body (e.g. in fibromyalgia)

MOVE

Active movement – is the range full and pain-free? Is the movement fluid? In the hands – can the patient perform fine movements? In the legs – can the patient walk properly?

Compare movements on the right and left side – are they symmetrical?

Is there crepitus when the joint is moved?

 If active movement is limited try passive movement. In a joint problem both will usually be affected. If it is a muscle or nerve problem passive movement may remain full.

Investigations

Investigations are unnecessary in many of the common musculoskeletal problems; the diagnosis is clear from the history and examination findings. Tests help to exclude another condition and to reassure the patient or their primary care physician.

Serum autoantibody studies

image Rheumatoid factors (RFs) (see also p. 518). Rheumatoid factors are detected by enzyme linked immunoabsorbent assay (ELISA). RFs are antibodies (usually IgM, but also IgG or IgA) against the Fc portion of IgG. They are detected in 70% of people with rheumatoid arthritis (RA), but are not diagnostic. RFs are detected in many autoimmune rheumatic disorders (e.g. SLE), in chronic infections, and in asymptomatic older people (Table 11.2).

image Anti-citrullinated peptide antibodies (ACPA). These antibodies are directed against citrullinated antigens, vimentin, fibrinogen, alpha enolase and type II collagen. They are measured by an ELISA technique and are present in up to 80% of people with RA. They have a high specificity for RA (90% with a sensitivity of 60%). They are helpful in early disease when the RF is negative to distinguish it from acute transient synovitis (see Box 11.6, p. 519). Positivity for RF and/or ACPA is associated with a worse prognosis and an increase in the likelihood of bony erosions in people with RA.

image Antinuclear antibodies (ANAs). These are detected by indirect immunofluorescent staining of fresh-frozen sections of rat liver or kidney or Hep-2 cell lines. Different patterns reflect a variety of antigenic specificities that occur with different clinical pictures (see Box 11.16, p. 537). ANA is used as a screening test for systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) – a negative ANA makes either condition highly unlikely – but low titres occur in RA and chronic infections and in normal individuals, especially the elderly (Table 11.3).

image Anti-double-stranded DNA (dsDNA) antibodies. These are usually detected by a precipitation test (Farr assay), by ELISA, or by an immunofluorescent test using Crithidia luciliae (which contains double-stranded DNA). Raised anti-dsDNA is highly specific for SLE and the levels usually rise and fall in parallel with disease activity so can be used to monitor the level of treatment required.

image Anti-extractable nuclear antigen (ENA) antibodies (see Box 11.16, p. 537). These produce a speckled ANA fluorescent pattern, and can be identified by ELISA. The most commonly measured ENAs are:

image Anti-neutrophil cytoplasmic antibodies (ANCAs) (see p. 544). These are predominantly IgG autoantibodies directed against the primary granules of neutrophil and macrophage lysosomes. They are strongly associated with small-vessel vasculitis. Two major clinically relevant ANCA patterns are recognized on immunofluorescence:

image Antiphospholipid antibodies (see p. 538). These are detected in the antiphospholipid syndrome (see p. 538).

image Immune complexes. Immune complexes are infrequently measured, largely because of variability between assays and difficulty in interpreting their meaning. Assays based on the polyethylene glycol precipitation method (PEG) or C1q binding are available commercially.

image Complement. Low complement levels indicate consumption and suggest an active disease process in SLE.

Table 11.2 Conditions in which rheumatoid factor is found in the serum

Autoimmune rheumatic diseases

RF (IgM) %

 Rheumatoid arthritis

 70

 Systemic lupus erythematosus

 25

 Sjögren’s syndrome

 90

 Systemic sclerosis

 30

 Polymyositis/dermatomyositis

 50

 Juvenile idiopathic arthritis

 Variable

Viral infections

Hyperglobulinaemias

 Hepatitis

 Chronic liver disease

 Infectious mononucleosis

 Sarcoidosis

 Cryoglobulinaemia

 

Chronic infections

Normal population

 Tuberculosis

 Elderly

 Leprosy
 Infective endocarditis

 Relatives of people with RA

 Syphilis

 

Table 11.3 Conditions in which serum antinuclear antibodies are found

  (%)

Systemic lupus erythematosus

95

Systemic sclerosis

70

Sjögren’s syndrome

80

Polymyositis and dermatomyositis

40

Rheumatoid arthritis

30

Juvenile idiopathic arthritis

Variable

Other diseases

 

 Autoimmune hepatitis

100

 Drug-induced lupus

>95

 Myasthenia gravis

50

 Idiopathic pulmonary fibrosis

30

 Diabetes mellitus

25

 Infectious mononucleosis

5–10

Normal population

8

Diagnostic imaging and visualization

image X-rays can be diagnostic in certain conditions (e.g. established rheumatoid arthritis) and are the first investigation in many cases of trauma. X-rays can detect joint space narrowing, erosions in rheumatoid arthritis, calcification in soft tissue, new bone formation, e.g. osteophytes and decreased bone density (osteopenia) or increased bone density (osteosclerosis):

1. In acute low back pain (see p. 503), X-rays are indicated only if the pain is persistent, recurrent, associated with neurological symptoms or signs, or worse at night or associated with symptoms such as fever or weight loss.

image Ultrasound (US) is particularly useful for periarticular structures, soft tissue swellings and tendons and for detecting active synovitis in inflammatory arthritis. It is increasingly used to examine the shoulder and other structures during movement, e.g. shoulder impingement syndrome (see p. 500). Doppler US measures blood flow and hence inflammation. US is used to guide local injections.

image Magnetic resonance imaging (MRI) shows bone changes and intra-articular structures in striking detail. Visualization of particular structures can be enhanced with different resonance sequences. T1-weighted is used for anatomical detail, T2-weighted for fluid detection and short tau inversion recovery (STIR) for the presence of bone marrow oedema. It is more sensitive than X-rays in the early detection of articular and periarticular disease. It is the investigation of choice for most spinal disorders but is inappropriate in uncomplicated mechanical low back pain. Gadolinium injection enhances inflamed tissue. MRI can also detect muscle changes, e.g. myositis.

image Computerized axial tomography (CT) is useful for detecting changes in calcified structures but dose of irradiation is high.

image Bone scintigraphy utilizes radionuclides, usually 99mTc, and detects abnormal bone turnover and blood circulation and, although nonspecific, helps in detecting areas of inflammation, infection or malignancy. It is best used in combination with other anatomical imaging techniques.

image DXA scanning uses very low doses of X-irradiation to measure bone density and is used in the screening and monitoring of osteoporosis.

image Positron emission tomography (PET) scanning uses radionuclides, which decay by emission of positrons. 18F-Fluorodeoxyglucose uptake indicates areas of increased glucose metabolism. It is used to locate tumours and demonstrate large vessel vasculitis, e.g. Takayasu’s arteritis (see p. 789). PET scans are combined with CT to improve anatomical details.

image Arthroscopy is a direct means of visualizing a joint, particularly the knee or shoulder. Biopsies can be taken, surgery performed in certain conditions (e.g. repair or trimming of meniscal tears), and loose bodies removed.

Common regional musculoskeletal problems (fig. 11.2)

Pain in the neck and shoulder (Table 11.4)

Mechanical or muscular neck pain (shoulder girdle pain)

Unilateral or bilateral muscular-pattern neck pain is common and usually self-limiting. It can follow injury, falling asleep in an awkward position, or prolonged keyboard working. Chronic burning neck pain occurs because of muscle tension from anxiety and stress.

Table 11.4 Pain in the neck and shoulder

Spondylosis seen on X-ray increases after the age of 40 years, but it is not always causal. Spondylosis can, however, cause stiffness and increases the risk of mechanical or muscular neck pain. Muscle spasm is palpable and tender and may lead to abnormal neck posture (e.g. acute torticollis). Muscular-pattern neck pain is not localized but affects the trapezius muscle, the C7 spinous process and the paracervical musculature (shoulder girdle pain). Pain often radiates upwards to the occiput and is commonly associated with tension headaches. These features are also seen in chronic widespread pain (see p. 509).

Nerve root entrapment

This is caused by an acute cervical disc prolapse or pressure on the root from spondylotic osteophytes narrowing the root canal.

Acute cervical disc prolapse presents with unilateral pain in the neck, radiating to the interscapular and shoulder regions. This diffuse, aching dural pain is followed by sharp, electric shock-like pain down the arm, in a nerve root distribution, often with pins and needles, numbness, weakness and loss of reflexes (Table 11.5).

Cervical spondylosis occurs in the older patient with posterolateral osteophytes compressing the nerve root and causing root pain (see Fig. 22.58, p. 1148), commonly at C5/C6 or C6/C7; it is seen on oblique radiographs of the neck. An MRI scan clearly distinguishes facet joint OA, root canal narrowing and disc prolapse.

Treatment

A support collar, rest, analgesia and sedation are used initially as necessary. Patients should be advised not to carry heavy items. It usually recovers in 6–12 weeks. MRI is the investigation of choice if surgery is being considered or the diagnosis is uncertain (Fig. 11.3). A cervical root block administered under direct vision by an experienced pain specialist may relieve pain while the disc recovers. Neurosurgical referral is essential if the pain persists or if the neurological signs of weakness or numbness are severe or bilateral. Bilateral root pain with or without long track symptoms or signs is a neurosurgical emergency because a central disc prolapse may compress the cervical spinal cord. Posterior osteophytes may cause spinal claudication and cervical myelopathy.

Whiplash injury

Whiplash injury results from acceleration–deceleration forces applied to the neck, usually in a road traffic accident when the car of a person wearing a seat belt is struck from behind. A simple decision plan based on clinical criteria helps to distinguish those most at risk and who warrant radiography. There is a low probability of serious bony injury if there is:

CT scans are reserved for those with bony injury. MRI scans occasionally show severe soft tissue injury. Whiplash injuries commonly lead to litigation.

Whiplash injury is a common cause of chronic neck pain, although most people recover within a few weeks or months. Delayed recovery depends in part upon the severity of the initial injury. The pattern of chronic neck pain is often complex, involving pain in the neck, shoulder and arm. Subjective symptoms such as headache, dizziness, and poor concentration sometimes accompany this. The subjective nature of these symptoms has led to controversy about their cause. The problem is more commonly seen in industrialized countries where the conflictive nature of the compensation process may actually delay recovery. Non-conflictive means of compensation may lead to a better prognosis.

Treatment is with reassurance (the patient is often distressed and anxious), analgesia, a short-term support collar and physiotherapy. Pain may take a few weeks or months to settle and the patient should be warned of this.

Pain in the shoulder

The shoulder is a shallow joint with a large range of movement. The humeral head is held in place by the rotator cuff (Fig. 11.4) which is part of the joint capsule. It comprises the tendons of infraspinatus and teres minor posteriorly, supraspinatus superiorly and teres major and subscapularis anteriorly. The rotator cuff (particularly supraspinatus) prevents the humeral head blocking against the acromion during abduction; the deltoid pulls up and the supraspinatus pulls in to produce a turning movement and the greater tuberosity glides under the acromion without impingement. Shoulder pathology restricts or is made worse by shoulder movement. Specific diagnoses are difficult to make clinically but this may not matter for pain management.

Pain in the shoulder can sometimes be due to problems in the neck. The differential diagnosis of this is shown in Box 11.1. Adhesive capsulitis (true frozen shoulder) is uncommon (see below). Early inflammatory arthritis and polymyalgia rheumatica in the elderly may present with shoulder pain. Shoulder pain is more common in diabetic patients than in the general population.

Rotator cuff (supraspinatus) tendonosis

This is a common cause of shoulder pain at all ages. It follows trauma in 30% of cases and is bilateral in under 5%. The pain radiates to the upper arm and is made worse by arm abduction and elevation, which are often limited. The pain is often worse during the middle of the range of abduction, reducing as the arm is raised fully; a so-called ‘painful arc syndrome’. When examined from behind, the scapula rotates earlier than usual during elevation. Passive elevation reduces impingement and is less painful. Severe pain virtually immobilizes the joint, although some rotation is retained (cf. adhesive capsulitis, see below). There is also painful spasm of the trapezius. There may be an associated subacromial bursitis. Isolated subacromial bursitis occurs after direct trauma, falling on to the outstretched arm or elbow. Acromioclavicular osteophytes increase the risk of impingement and may need to be removed surgically.

X-rays or ultrasound are necessary only when rotator cuff tendonosis is persistent or the diagnosis is uncertain.

Treatment

Analgesics, NSAIDs and/or physiotherapy may suffice, but severe pain responds to an injection of corticosteroid into the subacromial bursa (Fig. 11.4). Patients should be warned that 10% will develop worse pain for 24–48 hours after injection. Some 70% improve over 5–20 days and mobilize the joint themselves. Physiotherapy helps persistent stiffness. Further ultrasound-guided corticosteroid injections may be needed but the long-term benefit is unclear.

Pain in the hand and wrist (table 11.6)

Hand pain is commonly caused by injury or repetitive work-related activities. When associated with pins and needles or numbness it suggests a neurological cause arising at the wrist, elbow or neck. Pain and stiffness that are worse in the morning are due to tenosynovitis or inflammatory arthritis. The distribution of hand pain often indicates the diagnosis.

Table 11.6 Pain in the hand and wrist: causes

All ages Older patients

Trauma/fractures

Nodal OA:

Tenosynovitis:

 DIPs (Heberden’s nodes)

 Flexor with/without triggering

 PIPs (Bouchard’s nodes)
 First carpometacarpal joint

 Dorsal

 De Quervain’s
Carpal tunnel syndromeGanglionInflammatory arthritisRaynaud’s syndrome (p. 510)Chronic regional pain syndrome type I (in this chapter)

Trauma – scaphoid fracture

Pseudogout

Gout:

 Acute

 Tophaceous

 

DIPs, PIPs, distal and proximal interphalangeal joints.

Pain in the lower back

Low back pain is a common symptom. It is often traumatic and work-related, although lifting apparatus and other mechanical devices and improved office seating help to avoid it. Episodes are generally short-lived and self-limiting, and patients attend a physiotherapist or osteopath more often than a doctor. Chronic back pain is the cause of 14% of long-term disability in the UK. The causes are listed in Table 11.7, and the management of back pain is summarized in Box 11.2.

Table 11.7 Pain in the back (lumbar region): causes

Mechanical

Inflammatory

Metabolic

Neoplastic (see p. 589)

Referred pain

Mechanical low back pain

Mechanical low back pain starts suddenly, may be recurrent and is helped by rest. It is often precipitated by an injury and may be unilateral or bilateral. It is usually short-lived.

Examination and management

The back is stiff and a scoliosis may be present when the patient is standing. Muscular spasm is visible and palpable and causes local pain and tenderness. It lessens when sitting or lying. Pain relief and physiotherapy are helpful. Acupuncture helps some. Excessive rest should be avoided. Re-education in lifting and exercises help to prevent recurrent attacks of pain. Once a patient develops low back pain, although the episode itself is usually self-limiting, there is a significantly increased risk of further back pain episodes. Risk factors for recurrent back pain include:

Chronic low back pain is a major cause of disability and time off work and is reduced by appropriate early management.

Spinal movement occurs at the disc and the posterior facet joints, and stability is normally achieved by a complex mechanism of spinal ligaments and muscles. Any of these structures may be a source of pain. An exact anatomical diagnosis is difficult, but some typical syndromes are recognized (see below). They are often associated with but not necessarily caused by radiological spondylosis (see p.1148).

Postural back pain develops in individuals who sit in poorly designed, unsupportive chairs.

Lumbar spondylosis. The fundamental lesion in spondylosis occurs in an intervertebral disc, a fibrous joint whose tough capsule inserts into the rim of the adjacent vertebrae. This capsule encloses a fibrous outer zone and a gel-like inner zone. The disc allows rotation and bending.

Changes in the discs occasionally start in teenage years or early 20s and often increase with age. The gel changes chemically, breaks up, shrinks and loses its compliance. The surrounding fibrous zones develop circumferential or radial fissures. In the majority this is initially asymptomatic but visible on MRI as decreased hydration. Later the discs become thinner and less compliant. These changes cause circumferential bulging of the intervertebral ligaments.

Reactive changes develop in adjacent vertebrae; the bone becomes sclerotic and osteophytes form around the rim of the vertebra (Fig. 11.6). The most common sites of lumbar spondylosis are L5/S1 and L4/L5.

In young people, disc prolapse through an adjacent vertebral endplate produces a Schmorl’s node on X-ray. This is painless but may accelerate disc degeneration.

Spondylosis may be symptomless, but it can cause:

Facet joint syndrome. Lumbar spondylosis also causes secondary osteoarthritis of the misaligned facet joints. Pain is typically worse on bending backwards and when straightening from flexion. It is lumbar in site, unilateral or bilateral and radiates to the buttock. The facet joints are well seen on MRI and may show osteoarthritis, an effusion or a ganglion cyst. Direct corticosteroid injections into the joints under imaging may help but their long-term value is unclear. Physiotherapy to reduce hyperlordosis and reducing weight are helpful.

Fibrositic nodulosis. This causes unilateral or bilateral low back and buttock pain. There are tender nodules in the upper buttock and along the iliac crest. Such nodules are relevant only if they are tender. They are probably traumatic. Local, intralesional corticosteroid injections help.

Postural back pain and sway back of pregnancy. Low back pain is common in pregnancy and reflects altered spinal posture and increased ligamentous laxity. There is usually a hyperlordosis on examining the patient standing. Weight control and pre- and postnatal exercises are helpful, and the pain usually settles after delivery. Analgesics and NSAIDs are best avoided during pregnancy and breast-feeding. Epidurals during delivery are not associated with an increased incidence of subsequent back pain. Poor posture causes a similar syndrome in the non-pregnant, owing to obesity or muscular weakness. Poor sitting posture at work is a frequent cause of chronic low back pain.

Acute lumbar disc prolapse

The central disc gel may extrude into a fissure in the surrounding fibrous zone and cause acute pain and muscle spasm. These events are often self-limiting. A disc prolapse occurs when the extrusion extends beyond the limits of the fibrous zone (Fig. 11.6). The weakest point is posterolateral, where the disc may impinge on emerging spinal nerve roots in the root canal.

The episode often starts dramatically during lifting, twisting or bending and produces a typical combination of low back pain and muscle spasm, and severe, lancinating pains, paraesthesia, numbness and neurological signs in one leg (rarely both). The back pain is diffuse, usually unilateral and radiates into the buttock. The muscle spasm leads to a scoliosis that reduces when lying down. The nerve root pain develops with, or soon after, the onset. The site of the pain and other symptoms is determined by the root affected (Table 11.8). A central high lumbar disc prolapse may cause spinal cord compression and long tract signs (i.e. upper motor neurone). Below L2/L3 it produces lower motor neurone lesions.

On examination, the back often shows a marked scoliosis and muscle spasm. The straight-leg-raising test, whilst lying, is positive in a lower lumbar disc prolapse – raising the straight leg beyond 30° produces pain in the leg. Slight limitation or pain in the back limiting this movement is seen with mechanical back pain. Pain in the affected leg produced by a straight raise of the other leg suggests a large or central disc prolapse. Look for perianal sensory loss and urinary retention, which indicate a cauda equina lesion – a neurosurgical emergency (see p. 1135). An upper lumbar disc prolapse produces a positive femoral stretch test; pain in the anterior thigh when the knee is flexed in the prone position.

Osteoporotic crush fracture of the spine

Osteoporosis is asymptomatic but leads to an increased risk of fracture of peripheral bones, particularly neck of femur and wrist, and thoracic or lumbar vertebral crush fractures. Such vertebral fractures develop without trauma, after minimal trauma, or as part of a major accident. They may develop painlessly or cause agonizing localized pain that radiates around the ribs and abdomen. Multiple fractures lead to an increased thoracic kyphosis (‘widow’s stoop’). They cause disability and reduced QoL. The diagnosis is confirmed by X-rays, showing loss of anterior vertebral body height and wedging, with sparing of the vertebral endplates and pedicles. Bone oedema on MRI indicates that a fracture is recent. An underlying tumour and pathological fracture need to be excluded.

Treatment

Advise bed rest and analgesia until the severe pain subsides over a few weeks, then gradual mobilization. It may warrant hospitalization, and intravenous bisphosphonates or subcutaneous or nasal calcitonin are given to relieve pain. There may be some residual pain and deformity.

The role of percutaneous vertebroplasty and balloon kyphoplasty remains unclear: there are no randomized controlled trials showing any benefit. Both involve inserting a needle through a pedicle into the affected vertebral body under CT guidance with the aim of stabilizing the fracture. Kyphoplasty involves inflating a balloon filled with methyl methacrylate cement in order to restore vertebral shape. Vertebroplasty is the injection of cement alone, without restoring vertebral shape. Pain relief is usual with both but the risks are higher with vertebroplasty. Deciding when to intervene is complicated by the spontaneous recovery that many experience.

Bone density measurement and preventative treatment of osteoporosis are essential (see p. 555).

Pain in the hip (table 11.9)

‘Hip’ refers to a wide area between the upper buttock, trochanter and groin. It is useful to ask the patient to point to the site of pain and its field of radiation. Pain arising from the hip joint itself is felt in the groin, lower buttock and anterior thigh, and may radiate to the knee. Occasionally and inexplicably, hip arthritis causes pain only in the knee.

Table 11.9 Pain in the hip: causes

Hip region problems Main sites of pain

Osteoarthritis of hip

Groin, buttock, front of thigh to knee

Trochanteric bursitis (or gluteus medius tendonopathy)

Lateral thigh to knee

Meralgia paraesthetica

Anterolateral thigh to knee

Referred from back

Buttock

Facet joint pain

Buttock and posterior thigh

Fracture of neck of femur

Groin and buttock

Inflammatory arthritis

Groin, buttock, front of thigh to knee

Sacroiliitis (AS)

Buttock(s)

Avascular necrosis

Groin and buttocks

Polymyalgia rheumatica

Lumbar spine, buttocks and thighs

AS, ankylosing spondylitis.

Osteoarthritis (OA)

OA (see p. 512) is the most common cause of hip joint pain in a person over the age of 50 years. It causes pain in the buttock and groin on standing and walking. Stiff hip movements cause difficulty in putting on a sock and may produce a limp. Sudden onset pain may be associated with an effusion on MRI and can be treated by an ultrasound guided steroid injection.

Avascular necrosis (osteonecrosis) of the femoral head

This is uncommon but occurs at any age. (Risk factors are discussed on p. 556.) There is severe hip pain. X-rays are diagnostic after a few weeks, when a well-demarcated area of increased bone density is visible at the upper pole of the femoral head. The affected bone may collapse. Early, the X-ray is normal but bone scintigraphy or MRI demonstrates the lesion and shows bone marrow oedema.

Other

The knee is also a common site of inflammatory arthritis and osteoarthritis. Minor radiographic changes of osteoarthritis (see Fig. 11.11) are common in the over-50s and often coincidental, the cause of the pain being periarticular. Symptomatic osteoarthritis of the knee correlates poorly with the severity of the radiological changes.

Common periarticular knee lesions

Common intra-articular traumatic lesions of the knee

Knee joint effusions

An effusion of the knee causes swelling, stiffness and pain. The pain is more severe with an acute onset and with increasing inflammation, because of stretching of the capsule that contains the pain receptors. A full clinical history must include a past medical, family and drug history.

Inflammatory arthritis affects the knees and causes warmth and swelling. An acute inflammatory monoarthritis of the knee is a common presentation of a spondyloarthritis and occasionally is the first sign of RA.

Monoarthritis of the knee, associated with severe pain and marked redness, may be due to septic arthritis, or gout in the middle-aged male, or to gout or pseudogout in an older male or female. A cool, clear, viscous effusion is seen in elderly people with moderate or severe symptomatic OA (see p. 512).

Investigations

These are (a) blood tests, and (b) aspiration (Fig. 11.8) and examination of the knee effusion. The basic technique of aspiration is described in Practical Box 11.2.

Pain in the foot and heel (table 11.11)

The feet are subjected to extreme pressures by weight-bearing and inappropriate shoes. They are commonly painful. Broad, deep, thick-soled shoes are essential for sporting activities, prolonged walking or standing, and in people with congenitally flat or arthritic feet.

Table 11.11 Pain in the foot and heel: causes

Structural (flat (pronated) or high arched (supinated))

Hallux valgus/rigidus (±OA)

Metatarsalgia

Morton’s neuroma

Stress fracture

Inflammatory arthritis

 Acute, monoarticular – gout

 Chronic, polyarticular – RA

 Chronic, pauciarticular – spondyloarthritis

Tarsal tunnel syndrome

Heel pain

 Plantar fasciitis

Below heel

 Plantar spur

Below heel

 Achilles tendonitis/bursitis

Behind heel

 Sever’s disease

Behind heel

Arthritis of ankle/subtaloid joints

 

There are two common types of foot deformity:

The foot is affected by a variety of inflammatory arthritic conditions. After the hand, the foot joints are the most commonly affected by rheumatoid arthritis. The diagnosis depends upon careful assessment of the distribution of the joints affected, the pattern of other joint problems or by finding the associated condition (e.g. psoriasis, see p. 1207).

Chronic pain syndromes

Chronic pain syndromes (see p. 1163) are difficult to manage. Psychological factors are at least as relevant as inflammation or damage in determining the patient’s perception of pain. It is essential to be objective and non-judgemental when discussing physical, psychological and social factors without assuming which is primary. Chronic pain syndromes are difficult to explain scientifically. It is all too easy for a doctor to respond to this lack of a clear scientific cause by seeming to ‘blame’ the patient for the symptoms. Many chronic pain states are post-traumatic and some may be exacerbated partly by the process of litigation that may follow an injury.

Any chronic painful condition can change the way a person copes. Some people with chronic diseases or chronic pain cope well, but others adopt coping strategies and patterns of behaviour which make things worse. They become anxious, depressed or socially isolated, and their QoL is reduced. In chronic pain syndromes patients need help to lead a more normal life despite their pain, and are best referred to a specialist, multidisciplinary pain service.

Psychological states such as depression and anxiety produce physical symptoms, of which one is pain, while people with frank physical diseases are often understandably anxious and depressed. A biopsychosocial approach is best.

Chronic widespread pain (fibromyalgia)

Chronic widespread pain is defined as pain for more than three months both above and below the waist (p. 1163). It is a diagnosis of exclusion although it is still not universally accepted as a diagnosis. Multiple trigger points are reported by people with fibromyalgia (see p. 1163; Fig. 11.9). The pain is widespread, with unremitting, aching discomfort. Many patients have sleep disturbances, so they awake unrefreshed and have poor concentration. Multiple other symptoms, e.g. irritable bowel syndrome (IBS), tension headaches, dysmenorrhoea, atypical facial or chest pain, often co-exist. It occurs at any age and affects women more than men (7:1).

Doctors sometimes inappropriately label these patients ‘heart sink’ patients and patients sense this. The patient’s frustration is compounded by the fact that most tests are normal, and they fear doctors believe it is ‘all in their mind’. Sleep disturbance may lead to abnormalities of serotonin, substance P and cortisol levels. This is best regarded as a ‘wind up’ or pain amplification syndrome and is attributable to changes in the descending inhibitory pathways and in the spinal cord, resulting in a maladaptive pain response.

Chronic (work-related) upper-limb pain syndrome

This name is preferred to ‘repetitive strain injury’ (RSI). The predominant symptoms are pain in all or part of one or both arms. A specific lesion, such as tennis elbow or carpal tunnel syndrome, or muscular-pattern neck pain often develops first, and early recognition and treatment may prevent chronicity. After a variable period, the pain becomes more diffuse and no longer simply work-related, and there is often severe distress. It is seen in keyboard workers and in musicians. When it arises at work, it is often at a time of changing work practices, shortage of staff or disharmony. Middle managers find it difficult to deal with and this compounds the stress.

It is seen throughout the developed world. It peaked in incidence in Australia in the 1970s and 1980s but has largely disappeared there, apparently because of changes in work practices, improvements in early medical management, changes in workers’ compensation legislation, and reduced media discussion of the problem.

Hypermobility and hypermobility syndrome

Many people in the adult population have hypermobile joints (see p. 546). A small proportion are more prone to joint pains, joint instability and autonomic disturbances. This sometimes causes extreme anxiety and manifests as a chronic pain syndrome. Specific exercises to stabilize the joints, recognition of the problem and, sometimes, cognitive behavioral therapy all help. Surgery is best avoided because of problems with healing.

Chronic regional pain syndrome type I (previously called reflex sympathetic dystrophy or Sudeck’s atrophy)

This is defined as ‘a complex disorder or group of disorders that may develop as a consequence of trauma affecting the limbs, with or without obvious nerve lesions’. It may also develop after central nervous system lesions (e.g. strokes) or without cause. Its features are pain and other sensory abnormalities, including hyperaesthesia, autonomic vasomotor dysfunction, leading to abnormal blood flow and sweating, and motor system abnormalities. This leads to structural changes of superficial and deep tissues (trophic changes). Not all components need be present. The sensory, motor and sympathetic nerve changes are not restricted to the distribution of a single nerve and may be remote from the site of injury. The early phase, with pain, swelling and increased skin temperature, is difficult to diagnose but potentially reversible.

After a period of weeks or months, a second, still painful, dystrophic phase develops, characterized by articular stiffness, cold skin and trophic changes, often with localized osteoporosis.

A late phase involves continued pain, skin and muscle atrophy, and muscle contractures, and is extremely disabling.

Diagnosis is initially clinical – a high index of suspicion and recognizing the unusual distribution of the pain. A three-phase bone scan shows diffuse or patchy increase in uptake in the affected limb in all three phases. MRI also shows these early changes. Demineralization on X-ray occurs later.

Analgesic and anti-inflammatory drugs for musculoskeletal problems

The key to using drugs, particularly in chronic disorders and the elderly, is to balance risk and benefit and constantly to review their appropriateness. Box 11.3 shows the main drugs available.

image Box 11.3

Analgesics and NSAIDs

Analgesics (in order of potency) Advise that they be taken only if needed. Maximum doses are indicated here:

Paracetamol

500–1000 mg

6-hourly

Paracetamol (500 mg) and codeine (8–30 mg)

1–2 tablets

6-hourly

Dihydrocodeine

30–60 mg

Every 6–8 h

Paracetamol with dihydrocodeine

1–2 tablets

Every 6–8 h

Non-steroidal anti-inflammatory drugs (NSAIDs)

Always to be taken with food. Use slow-release preparations in inflammatory conditions or if more regular pain control is needed. Examples are:

Ibuprofen

200–400 mg

Every 6–8 h

Ibuprofen slow release

600–800 mg

12-hourly

Diclofenac

25–50 mg

8-hourly

Diclofenac slow release

75–100 mg

× 1–2 daily

Naproxen

250 mg

× 3–4 daily

Naproxen slow release

550 mg

× 2 daily

Celecoxiba

100–200 mg

× 2 daily

a COX-2-specific NSAID (coxib).

Non-steroidal anti-inflammatory drugs (NSAIDs)

NSAIDs have anti-inflammatory and centrally acting analgesic properties. They inhibit cyclo-oxygenase (COX), a key enzyme in the formation of prostaglandins, prostacyclins and thromboxanes (see Fig. 15.30). There are two specific cyclo-oxygenase enzymes:

Effects and side-effects

Most of the older NSAIDs are nonspecific and block both enzymes but with variable specificity (‘nonspecific NSAIDs’ or nsNSAIDs). Their therapeutic effect depends on blocking COX-2 and their side-effects mainly on blocking COX-1. COX-1 protects the gastric mucosa and blocking it accounts for the majority of upper gastrointestinal side-effects.

The most common side-effects with nonspecific NSAIDs are indigestion or skin rashes. More serious upper gastrointestinal side-effects are gastric erosions and peptic ulceration with perforation and bleeding. These occur more frequently in the elderly, in whom mortality is higher, in long-term use, and in those with high risk factors: a history of ulcers, Helicobacter pylori, and concurrent corticosteroids or anticoagulant therapy. Ibuprofen, in combination with low-dose aspirin, significantly increases the risk of severe gastrointestinal bleeding. Practice guidelines recommend proton pump inhibitors in high-GI-risk patients on nonspecific NSAIDs. H2 blockers are less effective as gastroprotective agents. Prostaglandin E2 analogues, e.g. misoprostol, reduce ulcer complications and are popular but may cause nausea and diarrhoea. Lower gastrointestinal (GI) side-effects of nonspecific NSAIDs are becoming more common.

COX-2 inhibitors (‘Coxibs’) produce fewer gastrointestinal side-effects but they still occur. Coxibs are used in patients who have a high risk of gastrointestinal disease and with no cardiovascular risk. People with a high risk of both may be better off taking an NSAID (ibuprofen or naproxen) or a Coxib with a proton pump inhibitor.

Coxibs and NSAIDs may reduce renal function, especially in the elderly (see Box 12.3, p. 608) and rarely cause cardiovascular events.

Osteoarthritis (OA)

Osteoarthritis is the most common type of arthritis. It occurs with a variety of patterns in synovial joints and is characterized by cartilage loss with an accompanying periarticular bone response. It is probably not a single disease entity but a multifactorial process in which mechanical factors have a central role. The whole joint structure including cartilage, subchondral bone, ligaments, menisci, synovium and capsule is involved. Pathologically, there is significant inflammation of articular and periarticular structures and alteration in cartilage structure. Osteoarthritis is the subject of intense investigation but no drugs which halt or reverse this process have yet been developed.

Aetiology (Box 11.4)

The gene that encodes collagen type II (COL2A1) is a candidate gene for familial OA but there is no single gene that associates with all patterns of OA. Abnormal local mechanical factors which affect loading and wear, such as prior injury, instability, hypermobility and joint dysplasia, play a role in most types of OA. Inflammation starting at periarticular entheses is seen during the inflammatory phase on MRI in nodal OA. Osteoarthritis is the result of active, sometimes inflammatory but potentially reparative processes rather than the inevitable result of trauma and ageing. Focal destruction of the articular cartilage is the common pathological feature. The spectrum of OA ranges from atrophic disease in which cartilage destruction occurs without any subchondral bone response, to hypertrophic disease in which there is massive new bone formation at the joint margins.

Cartilage is a matrix of collagen fibres, which enclose a mixture of proteoglycans and water (see p. 494). The gene for human aggrecan has been cloned, and polymorphisms of the gene have been correlated with OA of the hand in older men.

Cartilage is smooth-surfaced and shock-absorbing. Under normal circumstances, there is a dynamic balance between cartilage degradation by wear and its production by chondrocytes. Early in the development of OA, this balance is lost and, despite increased synthesis of extracellular matrix, the cartilage becomes oedematous. Focal erosion of cartilage develops. Chondrocytes die and, although repair is attempted from adjacent cartilage, the process is disordered. Eventually the synthesis of extracellular matrix fails and the surface becomes fibrillated and fissured. Cartilage ulceration exposes underlying bone to increased stress, producing microfractures and cysts. The bone attempts repair but produces abnormal sclerotic subchondral bone and overgrowths at the joint margins, called osteophytes (Fig. 11.11). There is some secondary inflammation.

Pathogenesis

Several mechanisms have been suggested:

image Abnormal stress and loading leading to mechanical cartilage damage play a role in secondary OA.

image Obesity is a risk factor for developing OA of the hand and knee, but not the hip in later life. Increased skeletal mass increases cartilage volume.

image Collagenases (MMP-1 and MMP-13) cleave collagen, and other metalloproteinases such as stromelysin (MMP-3) and gelatinases (MMP-2 and MMP-9) are also present in the extracellular matrix. MMPs are secreted by chondrocytes in an inactive form. Extracellular activation then leads to the degradation of both collagen and proteoglycans around chondrocytes.

image Tissue inhibitors of metalloproteinases (TIMPs) regulate the MMPs. Disturbance of this regulation may lead to an increase in cartilage degradation over synthesis and contribute to the development of OA. TIMPs have not yet proven to be of therapeutic value.

image Osteoprotegerin (OPG), RANK and RANK ligand (RANKL) control the remodelling of subchondral bone remodelling. Their levels are significantly different in OA chondrocytes. Inhibiting RANKL may prove a new therapeutic approach in OA.

image Aggrecanase production is stimulated by pro-inflammatory cytokines and aggrecan (the major proteoglycan) levels fall.

image Synovial inflammation is present in OA, and CRP in the serum may be raised. Interleukin-1 (IL-1) and tumour necrosis factor (TNF-α) release stimulates metalloproteinase production and IL-1 inhibits type II collagen production. IL-6 and IL-8 may also be involved. Anticytokine therapy has not yet been tested in OA. The production of cytokines by macrophages and of MMPs by chondrocytes in OA are dependent on the transcription factor NF-κB. Inhibition of NF-κB may have a therapeutic role in OA.

image IL-1 receptor antagonist genes are associated with radiographic severity of knee OA.

image Growth factors, including insulin-like growth factor (IGF-1) and transforming growth factor (TGF-β), are involved in collagen synthesis, and their deficiency may play a role in impairing matrix repair. However, increased TGF-β may cause increased subchondral bone density.

image Cartilage breakdown products lead to macrophage infiltration and vascular hyperplasia and IL1-β and TNF-α may contribute to further cartilage degradation.

image Vascular endothelial growth factor (VEGF) from macrophages is a potent stimulator of angiogenesis and may contribute to inflammation and neovascularization in OA. Innervation can accompany vascularization of the articular cartilage.

image Mutations in the gene for type II collagen (COL2A1) have been associated with early polyarticular OA.

image A strong hereditary element underlying OA is suggested by twin studies. Further studies may reveal genetic markers for the disease. The influence of genetic factors is estimated at 35–65%.

image In the Caucasian population there is an inverse relationship between the risk of developing OA and osteoporosis.

image Gender. In women, weight-bearing sports produce a two- to three-fold increase in risk of OA of the hip and knee. In men, there is an association between hip OA and certain occupations: farming and labouring. OA may flare after the female menopause or after stopping hormone replacement therapy.

image Periarticular enthesitis has been proposed as a factor in the pathogenesis of nodal generalized OA (NGOA; p. 515) and is the subject of investigation.

The term primary OA is sometimes used when there is no obvious known predisposing factor.

Box 11.4 shows some of the predisposing factors for the development of OA, and Table 11.12 shows other conditions that sometimes cause secondary arthritis.

Table 11.12 Causes of osteoarthritis

Primary OA

No known cause

Secondary OA

Pre-existing joint damage:

 Rheumatoid arthritis

 Gout

 Spondyloarthritis

 Septic arthritis

 Paget’s disease

 Avascular necrosis, e.g. corticosteroid therapy

Metabolic disease:

 Chondrocalcinosis

 Hereditary haemochromatosis

 Acromegaly

Systemic diseases:

 Haemophilia – recurrent haemarthrosis

 Haemoglobinopathies, e.g. sickle cell disease

 Neuropathies

Clinical subsets

Localized OA

Nodal OA (Table 11.13)

Joints of the hand are usually affected one at a time over several years, with the distal interphalangeal joints (DIPs) being more often involved than the proximal interphalangeal joints (PIPs). Nodal OA often starts around the female menopause. The onset may be painful and associated with tenderness, swelling and inflammation and impairment of hand function. At this stage, enthesitis can be seen on MRI. An intra-articular corticosteroid injection can be used at this stage, if deemed necessary. The inflammatory phase settles after some months or years, leaving painless bony swellings posterolaterally: Heberden’s nodes (DIPs) and Bouchard’s nodes (PIPs), along with stiffness and deformity (Fig. 11.12). Functional impairment is slight for most, although PIP osteoarthritis restricts gripping more than DIP involvement. On X-ray, the nodes are marginal osteophytes and there is joint space loss.

Table 11.13 Features of nodal OA

Thumb base OA co-exists with nodal OA and causes pain and disability, which decrease as the joint stiffens. The ‘squared’ hand in OA (Fig. 11.12) is caused by bony swelling of the carpometacarpal joint and fixed adduction of the thumb. Function is rarely severely compromised.

Polyarticular hand OA is associated with a slightly increased frequency of OA at other sites.

Hip OA

Hip OA (see p. 494) affects 7–25% of adult Caucasians but is significantly less common in black African and Asian populations. There are two major subgroups defined by the radiological appearance. The most common is superior-pole hip OA, where joint space narrowing and sclerosis predominantly affect the weight-bearing upper surface of the femoral head and adjacent acetabulum. This is most common in men and unilateral at presentation, although both hips may become involved because the disease is progressive. Early onset of hip OA is associated with acetabular dysplasia or labral tears. Less commonly, medial cartilage loss occurs. This is most common in women and associated with hand involvement (nodal generalized OA – NGOA), and is usually bilateral. It is more rapidly disabling.

Management

The guiding principle is to treat the symptoms and disability, not the radiological appearances; depression and poor quadriceps strength are better predictors of pain than is radiological severity in OA of the knee. Education of the individual about the disease and its effects reduces pain, distress and disability and increases compliance with treatment. Psychological or social factors alter the impact of the disease.

Inflammatory arthritis

Inflammatory arthritis (Table 11.14) includes a large number of arthritic conditions in which the predominant feature is synovial inflammation (Box 11.5). This disparate group includes post-viral arthritis, rheumatoid arthritis, spondyloarthritis, crystal arthritis, and Lyme arthritis. The diagnosis of these conditions is helped by the pattern of joint involvement (symmetrical or asymmetrical; large or small) (Table 11.14), along with any non-articular disease; a past and family history is helpful. The periodicity of the arthritis (single acute, relapsing, chronic and progressive) also helps in the diagnosis.

Table 11.14 Pattern of joint involvement in inflammatory arthritis

Diseases presenting as an inflammatory monoarthritis

Diseases presenting as an inflammatory polyarthritis

Certain non-articular diseases, e.g. psoriasis, iritis, inflammatory bowel disease, nonspecific urethritis or recent dysentery, suggest spondyloarthritis. There may be evidence of recent viral illness (rubella, hepatitis B or erythrovirus), of rheumatic fever, or a tick bite and skin rash (Lyme disease). In early arthritis, it may not be possible to make a specific diagnosis until the disease has evolved from an undifferentiated arthritis into a chronic form.

There is a distinct genetic separation of rheumatoid-pattern synovitis and spondyloarthritis; RA (see below) is associated with a genetic marker in the class II major histocompatibility genes, whilst spondyloarthritis shares certain alleles in the B locus of class I MHC genes, usually B27 (see p. 526).

In general, the pain and stiffness of inflammatory arthritis are worse in the morning often for several hours, in contrast to the much shorter morning stiffness of OA. Inflammatory markers (ESR and CRP) are often raised in inflammatory arthritis, and there is often a normochromic, normocytic anaemia. Specific types of arthritis are discussed below.

Rheumatoid arthritis (ra)

Rheumatoid arthritis is an autoimmune disease associated with autoantibodies to the Fc portion of immunoglobulin G (rheumatoid factor) and to citrullinated cyclic peptide. There is persistent synovitis, causing chronic symmetrical polyarthritis and systemic inflammation. Genetic studies suggest that RA is a heterogeneous group of diseases. Before the modern drug era it was rapidly disabling for most patients.

Aetiology and pathogenesis

The cause is multifactorial and genetic and environmental factors play a part.

image Gender. Women before the menopause are affected three times more often than men. After the menopause, the frequency of onset is similar between the sexes, suggesting an aetiological role for sex hormones. A meta-analysis of the use of the oral contraceptive pill has shown no effect on RA overall, but it may delay the onset of disease.

image Familial. The disease is familial with an increased incidence in first-degree relatives and a high concordance amongst monozygotic twins (up to 15%) and dizygotic twins (3.5%). In occasional families it affects several generations.

image Genetic factors account for about 60% of disease susceptibility. There is a strong association between susceptibility to RA and certain HLA haplotypes: HLA-DR4, which occurs in 50–75% of patients and correlates with a poor prognosis, as does possession of certain shared alleles of HLA-DRB1*04. The possession of these shared epitope alleles in HLA-DRB1 (S2 and S3P) increases susceptibility to RA and may predispose to anti-citrullinated peptide antibodies (ACPA). Citrullination is a process which modifies antigens, allowing them to fit into the shared epitope on HLA alleles. In a genome-wide association study in ACPA-positive RA, an association was found with loci near HLA-DRBI and PTPN22 in people of European descent. These genes affect the presentation of autoantigens (HLA-DRBI), T cell receptor signal transduction (PTPN22) and targets of ACPA (PAD14).

image Smoking is an environmental risk factor for seropositive RA, possibly by activation of the innate immune system.

Immunology

RA is primarily a synovial disease which invades local tissues and rheumatoid synovitis results when chemoattractants produced in the joint recruit circulating inflammatory cells. Overproduction and overexpression of tumour necrosis factors (TNF) is a key inflammatory element in RA, leading to synovitis and joint destruction. Interaction of macrophages and T and B lymphocytes drives this overproduction. TNF-α stimulates overproduction of interleukin-6 and other cytokines. Antibodies to TNF-α and IL-6 or specific blocking agents produce marked short-term improvement in synovitis, indicating the pivotal role of these cytokines in the chronic synovitis (see p. 523). These antibodies also reduce the malaise and tiredness felt in active RA. Interleukin-1 plays a bigger role in certain subsets, such as systemic juvenile idiopathic arthritis (see p. 545) and adult-onset Still’s disease (see p. 545).

An imbalance in the number of certain cell types appears to be central to immune regulation and its dysfunction.

image Synovial cells in chronic rheumatoid synovitis are predominantly abnormally behaving fibroblast-like synoviocytes, and macrophage-like synoviocytes which produce pro-inflammatory cytokines.

image Abnormal fibroblast-like synoviocytes appear to circulate between joints and may be the trigger for the polyarthritis.

image Osteoclasts play an active role in bone and cartilage destruction.

image B cells in the synovium, activated by cytokine-activated macrophages and T cells produce autoantibodies of which IgM and IgA RF is the most typical in RA. As RFs have the Fc portion of IgG as their antigen they have the potential for self aggregation and immune complex formation in the synovium. These may then trigger macrophages via IgGFc receptors to produce even more cytokines including IL-1, IL-8, TNF-α and granulocyte-macrophage colony-stimulating factor, and fibroblasts to produce IL-6.

image CD20 positive B cell ablation (a technique used for treating B cell lymphomas) induces temporary remission, reinforcing the central role of B cells in the chronic inflammation of RA. As the B cells return, the CRP rises and the disease flares again.

image Synovial fibroblasts have high levels of the adhesion molecule, vascular cell adhesion molecule (VCAM-1: a molecule which supports B lymphocyte survival and differentiation), decay accelerating factor (DAF: a factor that prevents complement-induced cell lysis) and cadherin-II (which mediates cell to cell interactions). These molecules may facilitate the formation of ectopic lymphoid tissue in synovium. Recent studies have shown that mice deficient in cadherin-II are resistant to a form of inflammatory arthritis. High-affinity antibodies are not a feature of RA, unlike other autoimmune diseases.

image T cells can be a part of the destructive process but other subsets reduce its severity. T cell-associated cytokines such as IL-2 and IL-4 are not present in high amounts and, when CD4-specific antibodies were used therapeutically to produce a specific helper T cell lymphopenia, they did not significantly alter the disease, suggesting that T cells play a lesser role. This treatment is no longer used. T17 helper cells (see p. 61), which produce IL-17A, 17F, 21 and 22 and TNF-α, may cause inflammation. The normal regulatory T cells are suppressed by TGP-β and interleukins (produced by macrophages and dendritic cells), allowing the T17 helper cells to increase.

image The role of innate immunity in RA pathogenesis and in predisposing the joint to inflammation are the subjects of increasing interest (see p. 51).

The triggering antigen, which leads to self-maintained inflammation in RA, remains unclear. Triggers for ACPA production include filaggrin, type II collagen and vimentin. There is little evidence that collagen type II is the triggering antigen, although it is a cause of arthritis in animal models of RA. Smoking is a potential trigger, particularly in ACPA-positive RA.

Pathology

Rheumatoid arthritis is typified by widespread persistent synovitis (inflammation of the synovial lining of joints, tendon sheaths or bursae). The normal synovium is thin and comprises a lining layer a few cells thick containing fibroblast-like synoviocytes and macrophages overlying loose connective tissue. The synoviocytes play a central role in synovial inflammation. In RA the synovium becomes greatly thickened and causes ‘boggy’ swelling around the joints and tendons. There is proliferation of the synovium into folds and fronds, and it is infiltrated by a variety of inflammatory cells, including polymorphs, which transit through the tissue into the joint fluid, and lymphocytes and plasma cells. There are disorganized lymphoid follicles. The normally sparse surface layer of lining cells becomes hyperplastic and thickened (Fig. 11.14). There is marked vascular proliferation. Increased permeability of blood vessels and the synovial lining layer leads to joint effusions that contain lymphocytes and dying polymorphs.

The hyperplastic synovium spreads from the joint margins on to the cartilage surface. This ‘pannus’ of inflamed synovium damages the underlying cartilage by blocking its normal route for nutrition and by the direct effects of cytokines on the chondrocytes. The cartilage becomes thinned and the underlying bone exposed. Local cytokine production and joint disuse combine to cause juxta-articular osteoporosis during active synovitis.

Fibroblasts from the proliferating synovium also grow along the course of blood vessels between the synovial margins and the epiphyseal bone cavity and damage the bone. This is shown by MRI to occur in the first 3–6 months following onset of the arthritis, and before the diagnostic, ill-defined juxta-articular bony ‘erosions’ appear on X-ray (Fig. 11.15). This early damage justifies the use of DMARDs (see p. 523) within 3–6 months of onset of the arthritis. Low-dose steroids delay and anti-TNF-α agents halt and occasionally reverse erosion formation. Erosions lead to a variety of deformities and contribute to long-term disability.

Rheumatoid factors (RFs) and anti-citrullinated peptide antibodies (ACPAs)

RFs (see p. 496) are circulating autoantibodies that have the Fc portion of IgG as their antigen. Transient production of RF is an essential part of the body’s normal mechanism for removing immune complexes, but in RA they show a much higher affinity and their production is persistent and occurs in the joints. They are of any immunoglobulin class (IgM, IgG or IgA), but the most common tests employed clinically detect IgM rheumatoid factor. Around 70% of people with polyarticular RA have IgM rheumatoid factor in the serum. Positive titres can predate the onset of RA.

The term ‘seronegative RA’ is used for patients in whom the standard tests for IgM rheumatoid factor are persistently negative. They tend to have a more limited pattern of synovitis.

IgM rheumatoid factor is not diagnostic of RA and its absence does not rule the disease out; however, it is a useful predictor of prognosis. A persistently high titre in early disease implies more persistently active synovitis, more joint damage and greater disability eventually, and justifies earlier use of DMARDs.

Anti-CCP antibodies (ACPA) (p. 497) are usually present with RF in RA. They are better predictors of a transition from early transient inflammatory arthritis to persistent synovitis and early RA. RF and the ACPA together are even more specific.

Clinical features of ra

Typical presentation

The most typical presentation of rheumatoid arthritis (approximately 70% of cases) begins as a slowly progressive, symmetrical, peripheral polyarthritis, evolving over a period of a few weeks or months. The patient is usually between 30 and 50 years of age, but the disease can occur at any age. Less commonly (15%) a rapid onset can occur over a few days (or explosively overnight) with a severe symmetrical polyarticular involvement, especially in the elderly. Factors which indicate a poor prognosis are listed in Box 11.6. The differential diagnosis of early RA is shown in Box 11.7.

Older classification criteria used to distinguish RA from other forms of arthritis (American College of Rheumatology, ACR criteria 1987) are now mainly used to ensure matched groups for research. The newer criteria that have replaced them are more suitable for assessing early arthritis because they do not rely on later changes such as erosions and extra-articular disease (Box 11.8).

image Box 11.8

ACR/EULAR 2010 criteria for RA

Criteria Points

1. Joint involvement

0–5

 1 medium to large joint

0

 2–10 medium to large joints

1

 1–3 small joints (large joints not counted)

2

 4–10 small joints (large joints not counted)

3

 >10 joints at least one small joint

5

2. Serology

0–3

 Negative RF and negative ACPA

0

 Low positive RF or low positive ACPA

2

 High positive RF or high positive ACPA

3

3. Acute-phase reactants

0–1

 Normal CRP and normal ESR

0

 Abnormal CRP or abnormal ESR

1

4. Duration of symptoms

0–1

 <6 weeks

0

 ≥6 weeks

1

The cut-off point for RA is at 6 or more points. Patients can also be classified as having RA if they have both typical erosions and longstanding disease previously satisfying the classification criteria. (Adapted from Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010; 376:1094–1108.)ACR, American College of Rheumatology

In early RA, the combination of at least one swollen joint for more than 6 weeks with no prior injury and no associated history or family history of spondyloarthritis or associated conditions such as psoriasis (see p. 1207) and a positive ACPA test is the best way to select patients for earlier treatment to avoid joint damage. This earlier treatment is evidence based and has been shown to reduce the risk of the development of damage and thus reduce permanent joint deformities.

Other presentations

The presentation and progression of RA is variable. Presentations are shown in Box 11.9. Relapses and remissions occur either spontaneously or on drug therapy. In some patients, the disease remains active, producing progressive joint damage. Rarely, the process may cease (‘burnt-out RA’).

Seronegative RA initially affects the wrists more often than the fingers and has a less symmetrical joint involvement. It has a better long-term prognosis, but some cases progress to severe disability. This form can be confused with psoriatic arthropathy, which has a similar distribution (p. 528).

Palindromic rheumatism is unusual (5%) and consists of short-lived (24–72 hours) episodes of acute monoarthritis. The joint becomes acutely painful, swollen and red, but resolves completely. Further attacks occur in the same or other joints. About 50% go on to develop typical chronic rheumatoid synovitis after a delay of months or years. The rest remit or continue to have acute episodic arthritis. The detection of RF or ACPA predicts conversion to chronic, destructive synovitis.

Joint involvement in RA

The changes described below are seen in established disease or when early drug treatment has been ineffective.

Shoulders

RA commonly affects the shoulders. Initially, the symptoms mimic rotator cuff tendonosis (see p. 500) with a painful arc syndrome and pain in the upper arms at night. As the joints become more damaged, global stiffening occurs. Late in the disease rotator cuff tears are common (see p. 501) and interfere with dressing, feeding and personal toilet.

Knees

Massive synovitis and knee effusions occur, but respond well to aspiration and steroid injection (see p. 507). A persistent effusion increases the risk of popliteal cyst formation and rupture (see p. 508). In later disease, erosion of cartilage and bone causes loss of joint space on X-ray and damage to the medial and/or lateral and/or retropatellar compartments of the knees. Depending on the pattern of involvement, the knees may develop a varus or valgus deformity. Secondary OA follows. Total knee replacement is often the only way to restore mobility and relieve pain.

Non-articular manifestations (Fig. 11.18)

Less common non-articular manifestations

Non-articular complications are becoming less common, probably because of more effective disease control.

Management of ra (box 11.10)

The diagnosis of RA inevitably causes concern and fear in the patient and requires a lot of explanation and reassurance. Most guidelines suggest that anyone with early inflammatory arthritis should be referred to a specialist arthritis clinic within 3 months of onset, whenever possible.

The doctor should have a positive approach and remind the patient that with the help of drugs most people continue to lead a more or less normal life, despite their arthritis; 25% will recover completely. The earliest years are often the most difficult and people should be helped and encouraged to stay at work during this phase if possible. Uncertainty about remissions and flares and the impact of drug treatment makes planning difficult. However, patients adjust remarkably with time and support; the specialist team in a rheumatology unit (including doctors, nurses, physiotherapists, podiatrists and psychologists) helps patients learn to cope. Leaflets, websites and local patient groups also provide helpful advice.

Patients from socially deprived backgrounds and smokers have a worse prognosis. Statins have been shown to be of benefit in reducing cardiovascular risk and possibly inflammation whatever the cholesterol level; more studies are required.

Drug therapy

There is no curative agent available for RA but drugs are now available that prevent disease deterioration. Symptoms are controlled with analgesia and NSAIDs. Data now support the use of DMARDs early in the disease to prevent the long-term irreversible damaging effects of inflammation of the joints, and drugs that block TNF-α and IL-1 and the use of B cell ablation with rituximab are revolutionizing the management of RA. Searching for persistent synovitis in patients in apparent remission using Doppler ultrasound is leading to more intensive therapeutic regimes which will potentially reduce longer-term disability.

Non-steroidal anti-inflammatory drugs (NSAIDs) and coxibs

Most people with RA are unable to cope without an NSAID to relieve night pain and morning stiffness. NSAIDs do not reduce the underlying inflammatory process. They all act on the cyclo-oxygenase (COX) pathway (see Fig. 15.30). The individual response to NSAIDs varies greatly. It is desirable therefore to try several different drugs for a particular patient in order to find the best (Box 11.13). Each compound should be given for at least a week. Start with an inexpensive NSAID with few side-effects and with which you are familiar. Regular doses are needed to be effective. The major side-effects of NSAIDs and the use of coxibs are discussed on page 511. If gastrointestinal side-effects are prominent, or the patient is over 65 years of age, add a proton pump inhibitor. Slow-release preparations (e.g. slow-release diclofenac, 75 mg, taken after supper), or a suppository at bedtime, usually work well. For additional relief, a simple analgesic is taken as required (e.g. paracetamol or a combination of codeine or dihydrocodeine and paracetamol). Many patients need night sedation.

Corticosteroids

There is evidence to suggest that the early use of corticosteroids slows down the course of the disease but intensive short courses in very early arthritis do not appear to stop progressive disease. Corticosteroids are the commonest cause of secondary osteoporosis. Treatment for more than 3 months or with repeated courses is a risk, and concomitant calcium with vitamin D and bisphosphonates is necessary.

Intra-articular injections with semicrystalline steroid preparations have a powerful but sometimes only short-lived effect.

Intramuscular depot injections (40–120 mg depot methylprednisolone) help whilst waiting for DMARDs to work and to control severe disease flares, or they can be used before a holiday or other life event. They should be used infrequently.

Oral corticosteroids have a number of problems (Boxes 11.11 and 19.11). They are powerful disease-controlling drugs, but are avoided in the long term because side-effects are inevitable. Early intensive short-term regimens are often used. Doses of 5–7.5 mg daily as maintenance therapy are used in some centres. Corticosteroids are invaluable to people with severe disease with extra-articular manifestations such as vasculitis.

Disease-modifying anti-rheumatic drugs (DMARDs)

DMARDs, prescribed by a rheumatologist, are listed in Table 11.16 (see also Fig. 11.19).

DMARDs are used as early as possible once RA has been diagnosed. Studies suggest that early intervention with DMARDs at 6 weeks to 6 months improves the outcome. Combinations of three or four drugs (steroids, sulfasalazine, methotrexate and hydroxychloroquine) in early RA are increasingly common, reducing the number of agents once remission has been achieved. Most DMARDs are contraindicated in pregnancy (Box 11.13). Effective treatment with DMARDs reduces the increased cardiovascular risk seen in people with RA.

Cytokine modulators

TNF-α blockers. The availability of agents that block TNF-α has significantly changed the traditional use of DMARDs. Because of their cost they are used after at least two DMARDs (usually sulfasalazine and methotrexate) have been tried. They represent a major therapeutic advance, although not all patients respond and there is loss of efficacy in some responders. They are usually given in combination with methotrexate to reduce loss of efficacy due to antibody formation.

These products slow or halt erosion formation in up to 70% of people with RA and produce healing in a few. Malaise and tiredness improve in a manner that is not seen with other DMARDs. Secondary failure occurs with all in the first year and changing to another anti-TNF agent is justified and often regains control of the disease. Potential biomarkers for responsiveness are being studied. Failure to respond to one does not predict failure to others.

Side-effects. Many patients on cytokine modulators are entered into a long-term observational study in the UK and other countries to monitor for potential side-effects. To date, the results are reassuring. People with severe RA are at slightly increased risk of lymphoma and this is being carefully monitored. There is no convincing evidence of any increased risk of other cancers. A few people become ANA positive and develop a reversible lupus-like syndrome, leucocytoclastic vasculitis, some extracutaneous involvement or interstitial lung disease. Reactivation of old TB may occur but is probably less common with etanercept. A pre-treatment chest X-ray is recommended, with a specialist review for high-risk groups. TB should be treated before using these agents and a course of prophylaxis is used in latent disease. There is an increased risk of chest infections which requires close monitoring. Hepatitis B and C infection requires careful risk analysis and regular aminotransferase monitoring if anti-TNF agents are prescribed. They should not be used in patients who have severe cardiac failure.

These agents are extremely expensive when compared with traditional DMARDs but they may save costs in the longer term by reducing disability and the need for hospitalization. Their use should be restricted to specialist centres. To date there is no evidence of an adverse effect on pregnancy outcome but care is essential.

Other cytokine modulators

Rituximab is a genetically engineered chimeric monoclonal antibody (p. 72) that causes lysis of CD20-positive B cells. CD20 is a pan-B cell surface antigenic phosphoprotein. Its expression is restricted to pre-B and mature B cells but it is not present on stem cells and is lost before differentiation into plasma cells. Rituximab produces significant improvement in RF-factor positive RA for 8 months to several years when used alone or in combination with corticosteroids and/or methotrexate. This is associated with a 6–9-month B cell lymphopenia with little change in circulating immunoglobulins. A re-flare is often accompanied by a return of peripheral lymphocytes and a rise in CRP. Rituximab can be reused as the disease flares. Repeated courses over up to 5 years are acceptable and well tolerated and around 80% of RF-positive patients respond with 50–60% showing persistent disease control. It is worth trying in patients who have failed to respond to anti-TNF agents. There may be an increased risk of chest infections, and immunoglobulin levels may fall progressively and need to be monitored.

Abatacept is a recombinant fusion protein of CTLA4 and the Fc portion of IgG1, which selectively modulates T cell activation by costimulation blockade. It may have an important role in patients who do not respond to anti-TNF regimens.

Tocilizumab is a humanized monoclonal anti-IL-6 receptor antibody and is used with methotrexate for moderate to severe RA after at least one other cytokine modulator has failed.

Anakinra is a human recombinant IL-1 receptor antagonist which is used in combination with methotrexate. It has been used after anti-TNF agents have been unsuccessful, but is now only recommended for clinical studies.

Spleen tyrosine kinase (SYK) inhibitor given orally has been effective in RA in phase 2 studies.

Share this: